Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Classical hematology 1

Conditions

Fanconi Anemia 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Lymphoma, Non-Hodgkin 1Colorectal Neoplasms 1Anus Neoplasms 1

Interventions

Doxorubicin 33pembrolizumab 16Gemcitabine 15eribulin 10Irinotecan 10olaratumab 9Trabectedin 9pazopanib 8Docetaxel 8Injections 7Cyclophosphamide 7Nivolumab 6Fluorouracil 6anlotinib 5Temozolomide 5Ipilimumab 5Ifosfamide 5Bevacizumab 5tazemetostat 4ridaforolimus 4Drug Therapy 4Cetuximab 4Carboplatin 4toripalimab 3surufatinib 3spartalizumab 3ganitumab 3entrectinib 3conatumumab 3belinostat 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Sarcoma × SRA737 × Clear all
NCT02797977 2023-06-22

A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects

Sierra Oncology LLC - a GSK company

Phase 1/2 Completed
153 enrolled
Classical hematologySarcomaThoracic

Fanconi Anemia, Sarcoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡